Liraglutide OverviewLiraglutide (NN2211) is a derivative of human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1) that is used as a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing a separate strength in the U.S. and E.U...
Read more Liraglutide Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Liraglutide
Recent Liraglutide Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 6mg/ml
- Solution: 0.6mg, 18mg/3ml (6mg/ml)
NDC Database Records for Liraglutide: (1 result)Sorted by National Drug Code
- 0169-2800 Saxenda 6 mg/ml Subcutaneous Injection, Solution by Novo Nordisk
Other drugs which contain Liraglutide or a similar ingredient: (4 results)
- SAXENDA Liraglutide Recombinant
- VICTOZA Liraglutide16 discussions
- INSULIN DEGLUDEC + LIRAGLUTIDE
- XULTOPHY Insulin Degludec + Liraglutide